These are links to research and trials into new techniques which might be relevant to treating HLRCC in the future.

Regenerative medicine

This is the "process of replacing or regenerating human cells, tissues or organs to restore or establish normal function". This field holds the promise of regenerating damaged tissues and organs in the body by replacing damaged tissue and/or by stimulating the body's own repair mechanisms to heal previously irreparable tissues or organs. Regenerative medicine also empowers scientists to grow tissues and organs in the laboratory and safely implant them when the body cannot heal itself. Importantly, regenerative medicine has the potential to solve the problem of the shortage of organs available for donation compared to the number of patients that require life-saving organ transplantation, as well as solve the problem of transplantation rejection, since the organ's cells will match that of the patient. See

This site describes many of the researches being undertaken.


Characterisation of the Oncogenic Signaling Cascade in Fumarate Hydratase Deficient Cancer Cells Using Subcellular-resolved Systems Biology Approaches Investigators - Kathryn Lilley, Christian Frezza, and Julio Saez-Rodriguez, 2014

This is defining a project with
Aim 1. Identification of signaling pathways affected by FH deficiency using phospho-proteomics and subcellular proteomics.
Aim 2. Metabolic characterization of FH-deficient cells.
Aim 3. Build a predictive and mechanistic mathematical model of the interplay of signal transduction and metabolism.

Targeting ABL1-Mediated Oxidative Stress Adaptation in Fumarate Hydratase-Deficient Cancer. Sourbier C, Ricketts CJ, Matsumoto S, Crooks DR, Liao PJ, Mannes PZ, Yang Y, Wei MH, Srivastava G, Ghosh S, Chen V, Vocke CD, Merino M, Srinivasan R, Krishna MC, Mitchell JB, Pendergast AM, Rouault TA, Neckers L,and Linehan WM, 2014

This artical identifies another possible therapeutic target for treating HLRCC kidney cancer. This is a link to the abstract, the full article is available on subscription. Treatment with vandetanib/metformin on mice has been very successful and a clinical trial is expected soon.


Gene Therapy Dr Richard Harbottle

This is exciting new research called S/MAR Plasmid Vectors for Genetic Correction from Imperial College, London. This research was presented at the 3rd International BHD Symposium May 2011.


Israel Develops Cancer Vaccine is described in these links:

Medical Breakthrough: Israel is Developing Cancer Vaccine

Vaccine could work against 90% of cancer types

'Universal' cancer vaccine developed

In a breakthrough development, the Israeli company Vaxil BioTherapeutics has formulated a therapeutic cancer vaccine, now in clinical trials at Hadassah University Medical Center in Jerusalem. If all goes well, the vaccine could be available about six years down the road, to administer on a regular basis not only to help treat cancer, but in order to keep the disease from recurring. The first safety trial of 10 patients has encouraging results April 10, 2012. The vaccine is being tested against a type of blood cancer called multiple myeloma. If the substance works as hoped — and it looks like all arrows are pointing that way — its platform technology VaxHit could be applied to 90 per cent of all known cancers, including prostate and breast cancer, solid and non-solid tumors. It may or may not be effective in HLRCC.


Cancer researcher Marston Linehan discusses role of genetics Christian Torres, Washington Post 2011

"Marston Linehan, chief of urologic oncology at the National Cancer Institute, bridges the gap between genetics research and treatments for cancer."

JX-594 Intravenous Viral Therapy Phase I

Published in September 2011 Nature - A new type of cancer treatment that uses a virus to infect and destroy tumor cells without harming normal cells is showing promise in early clinical trials.

Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase Christian Frezza, Liang Zheng,Ori Folger, Kartik N. Rajagopalan, Elaine D. MacKenzie, Livnat Jerby, Massimo Micaroni, Barbara Chaneton, Julie Adam, Ann Hedley, Gabriela Kalna, Ian P. M. Tomlinson, Patrick J. Pollard, Dave G. Watson, Ralph J. Deberardinis, Tomer Shlomi,Eytan Ruppin, Eyal Gottlieb, 2011

This is exciting new research describing a cell pathway which when blocked in a HLRCC cancer cell will cause that cell to die, but allow normal cells to live.


Oncogenes and Human Cancer: The Next 25 Years

This is not specific to HLRCC, but shows the work of the great team of world experts in giving us all hope for the future.

Copyright © 2004 - 2018 Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC)Family Alliance
c/o VHL Alliance, 1208 VFW Parkway // Suite 303, Boston, MA 02132
+1-617-277-5667 ext. 3 or +1-800-767-4845, ext. 3

Last modified: December 13 2017 22:29:32.